RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03627572|
Recruitment Status : Recruiting
First Posted : August 13, 2018
Last Update Posted : August 13, 2018
The REspiratory Syncytial virus Consortium in EUrope (RESCEU) is an Innovative Medicine Initiative (IMI) effort funded by the EU under the H2020 framework to define and understand the burden of disease caused by human respiratory syncytial virus (RSV) infection. RSV causes severe disease in individuals at the extremes of the age spectrum and in high risk groups. It was estimated that RSV was associated with 34 million cases of acute respiratory tract infection (ARTI), 3.4 million ARTI hospitalizations and 55,000 to 199,000 deaths in children <5 years in 2005 worldwide. These estimates were based on limited data and there is a substantial gap in knowledge on morbidity and associated healthcare and social costs in Europe. New vaccines and therapeutics against RSV are in development and will soon be available on the European market. RESCEU will deliver knowledge of the incidence and burden of disease RSV in young children and older adults in Europe, which is essential for stakeholders (governments, etc) to take decisions about prophylaxis and treatment.
To determine the burden of disease due to RSV in young children.
Prospective epidemiological, observational, multi-country, multicenter cohort study.
Birth cohort of healthy infants (follow-up from birth until the age of 3 years maximum):
- Passive birth cohort (n=9,000).
- Active birth cohort (n=1,000).
Main study parameters/endpoints:
The primary endpoint of the study is the incidence of RSV infection-associated ARTI, RSV associated medically attended (MA) ARTI (active birth cohort) and RSV related hospitalization (passive birth cohort) in infants (< 1 year) during 3 RSV seasons. In addition, a major secondary endpoint is RSV attributable burden of wheezing.
|Condition or disease||Intervention/treatment|
|RSV Infection Respiratory Syncytial Virus Infections RSV Bronchiolitis||Other: No intervention|
This will be a multi-country, multicenter, prospective, observational cohort study conducted across 3 consecutive years to determine the incidence of RSV infection, RSV associated MA-ARTI and RSV related hospitalization in a birth cohort of healthy subjects, recruited from the general population.
At birth parents will be asked by a member of the study team to participate in the active cohort. If enrolled, a nasopharyngeal sample, a blood sample, a buccal sample, and urine and stool samples will be collected from the baby in the first week after birth. The blood sample will be collected by means of a heel prick or a venepuncture, if possible, in combination with an already scheduled moment of blood sampling. Respiratory tract symptoms will be assessed weekly during the RSV season by telephone or email or (daily) telephone app. If a child experiences a new episode of ARTI according to the parents, the study team will visit the child to collect a nasopharyngeal sample, 200µl is used to perform a point of care (POC) test for RSV, and the rest will be stored for additional viral testing by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). If RSV is positive, parents will be asked informed consent to obtain additional blood, nasopharyngeal, urine and stool samples at the time of RSV infection and 6-8 weeks after RSV infection.
Parents of all children in the active cohort will be asked yearly to fill in a questionnaire until age 3 years maximum or till end of study (defined as the moment that the last included subject has been followed up for 12 months).
If parents decline to participate in the active birth cohort, informed consent will be asked for passive follow up. Parents of participants in passive follow-up will be asked to fill in a questionnaire at birth and after one year. If their child was admitted to the hospital because of an ARTI, clinical data will be collected retrospectively from the hospital. Participating hospitals will perform RSV tests as part of standard diagnostic care in children <1 year of age who are admitted with ARTI. Only children with hospitalization due to ARTI will be followed up by a yearly questionnaire until age 3 years maximum or till end of study (defined as the moment that the last included subject has been followed up for 12 months).
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||REspiratory Syncytial Virus Consortium in EUrope (RESCEU) Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe.|
|Actual Study Start Date :||July 21, 2017|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||December 31, 2020|
Active cohort (N=1000)
Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
Other: No intervention
Not applicable (no intervention)
Passive cohort (N=9000)
Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
Other: No intervention
Not applicable (no intervention)
- Number of participants with a Medically attended RSV acute lower respiratory tract infection (MA-RSV-ALRI) based on a positive RT-PCR for RSV who visit a clinician during the RSV-ALRI. [ Time Frame: In the active cohort during the RSV season (Oct-May), for all participants after 1 year (questionnaire) ]Lower respiratory tract infection proven to be caused by RSV for which medical consultation (general practitioner/specialist/hospitalization) is required. RSV infection is confirmed using RT-PCR from a nasal swab collected by the study team in the active cohort in case of respiratory infection. In the passive cohort, this information is collected from medical data from the hospital in case of hospitalization.
- Number of participants with a RSV hospitalization (hospitalization with RT-PCR confirmed RSV). [ Time Frame: In the active cohort during the RSV season (Oct-May), for all participants after 1 year (questionnaire) ]Hospitalization for a respiratory tract infection proven to be caused by RSV. This information is collected from the hospital data. RSV must be confirmed by RT-PCR.
- Number of participants with an RSV infection [ Time Frame: Active cohort only, during the RSV season (Oct-May) ]Incidence of RSV outside of the medical setting (active cohort only). When participants experience respiratory symptoms, the study team plans a visit to perform RSV diagnostics (nasopharyngeal swab).
- RSV-related wheeze incidence [ Time Frame: The incidence of wheeze will be determined by annual questionnaires at age 1 year, 2 years and 3 years (active cohort and all children hospitalized for ARTI) maximum or till end of study. ]To estimate the incidence and frequency of RSV-related wheeze up to age 3 years. Wheeze will be assessed in questionnaires during the winter season follow-up (active cohort) and after the one, two and three years of follow-up (active and passive cohort).
- RSV related wheeze sequelae [ Time Frame: Severity of wheeze will be determined by annual questionnaires at age 1 year, 2 years and 3 years (active cohort and all children hospitalized for ARTI) maximum or till end of study. ]To estimate how RSV infection of different severity relates to occurence of wheeze up to age 3 years. Wheeze will be assessed in questionnaires during follow-up (active cohort) and after the one year of follow-up (active and passive cohort). Severity characteristics of wheeze are asked such as wheeze without other symptoms and medically attended wheeze.
- All cause MA-ARTI [ Time Frame: annual questionnaire at age 1 year (all participants) ]To determine the rate of all-cause medically attended (inpatient or outpatient) ARTI (active cohort).To determine mortality (RSV associated and all-cause) through all RSV seasons of follow up (all).
- Effect of RSV on health care cost [ Time Frame: Questionnaires during the first year of life (all), and up to 3 years of age (active cohort, RSV+ cases) ]To determine health care costs and health care resource use in RSV-associated and all-cause medically attended (inpatient or outpatient) ARTI patients. Data is collected on hospitalization, duration of hospitalization, treatment given (respiratory support, antibiotics) and outpatient visits.
- Effect of all-cause ARTI on health care cost [ Time Frame: Questionnaires during the first year of life (all), and up to 3 years of age (active cohort) ]To determine health care costs and health care resource use in all-cause medically attended (inpatient or outpatient) ARTI patients. Data is collected on hospitalization, duration of hospitalization, treatment given (respiratory support, antibiotics) and outpatient visits.
- RSV related secondary bacterial infections and the use of antibiotics [ Time Frame: Hospitalization case report form (CRF) (1 year, all participants), active follow-up during the RSV season in the first year of life in the active cohort. ]To determine the incidence of RSV-related secondary bacterial respiratory tract infections within 21 days after onset of RSV infection and their association with antibiotic use in hospitalized RSV ARTI patients (all children) and non-hospitalized RSV ARTI patients (active cohort).
- Sample collection for biomarker research (blood, nasal swab, nasopharyngeal swab, urine, faeces, buccal swab) [ Time Frame: This is collected at baseline (around the 5th day of life) for active participants and in case of an RSV infection during the winter season. ]To collect clinical samples (blood, nasal swab, nasopharyngeal swab, urine, faeces, buccal swab) for biomarker analysis. This is collected at baseline (around the 5th day of life) for active participants and in case of an RSV infection during the winter season.
- Incidence of other respiratory pathogens [ Time Frame: Hospitalization CRF (1 year all participants) ]To determine the incidence rate of other respiratory pathogens (influenza, rhinovirus, human metapneumovirus, parainfluenzavirus, etc.) associated with all medically attended (inpatient or outpatient) ARTI (active cohort).
- Proportion of RSV in viral ARTI [ Time Frame: active follow-up during the RSV season in the first year of life in the active cohort. ]To determine the proportion of viral ARTI attributable to RSV (active cohort).
- Risk factors for (severe) RSV infection [ Time Frame: Questionnaires baseline/1 year/hospitalization, for all participants ]To determine important risk factors for RSV infection. Clinical risk factors will be assessed to see their association with severe RSV infection, defined as RSV-related hospitalization.
- Effect of RSV on Health-Related Quality of Life (HRQoL) [ Time Frame: Quality of Life is assessed at baseline, during the RSV season and after 1,2,3 years of life. ]Effect of an RSV infection on the quality of life of the child and it's parents. In various questionnaires the standardized EuroQol questionnaire is used to assess the quality of life. The questionnaire contains questions on mobility, self-care, usual activities, pain/discomfort, anxiety and worries about the child, as well as a scale to assess their current health and the health of their child from 0-100 (0 being the worst health imaginable, and 100 the best health possible).
Biospecimen Retention: Samples With DNA
- Blood sample (serum/paxgene/whole blood)
- Buccal sample
- Nasopharyngeal sample (microbiome)
- Nasopharyngeal sample (viral testing)
- Urine sample
- Stool sample
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03627572
|Contact: Louis Bont, Prof. Dr.||+firstname.lastname@example.org|
|Contact: Joanne Wildenbeest, Dr.||+email@example.com|
|Varsinais-Suomen sairaanhoitopiirin kuntayhtymä (Turku University Hospital)||Recruiting|
|Turku, Finland, FI-20520|
|Contact: Terho Heikkinen, MD, PhD +358-50-5359095 firstname.lastname@example.org|
|University Medical Centre Utrecht||Recruiting|
|Utrecht, Netherlands, 3584 CX|
|Contact: Louis J Bont, MD, PhD +3188-7554091 email@example.com|
|Contact: Joanne G Wildenbeest, MD, PhD +3188-7563776 firstname.lastname@example.org|
|Sub-Investigator: Koos Korsten, MD|
|Sub-Investigator: Roy Zuurbier, MD|
|Sub-Investigator: Marlies van Houten, MD|
|Servicio Galego de Saúde (SERGAS)||Recruiting|
|Santiago De Compostela, Spain, 15706|
|Contact: Federico Martinón-Torres, MD, PhD 0034- 981-955093 Federico.Martinon.Torres@sergas.es|
|University of Edinburgh||Recruiting|
|Edinburgh, United Kingdom|
|Contact: Steve Cunningham, MD, PhD 0131 536 0808 email@example.com|
|Contact: Julie Baggott 0131 536 0808 Julie.Baggott@nhslothian.scot.nhs.uk|
|University of Oxford, Oxford Vaccine Group||Recruiting|
|Oxford, United Kingdom, OX3 7LE|
|Contact: Andrew J Pollard, Prof. MD. 0044 (0)1865 611400 firstname.lastname@example.org|
|Contact: Hannah Robinson 07766 922492 email@example.com|
|Sub-Investigator: Matthew Snape, MD|
|Sub-Investigator: Simon Drysdale, MD|
|Principal Investigator:||Louis Bont, Prof. Dr.||University Medical Centre Utrecht (UMCU)|